Research chemicals, novel psychoactive substances (NPS), designer drugs: three names for the same grey zone, the psychoactive molecules that imitate, extend or sidestep the scheduled classics. This page is not a catalogue. It is a risk map: why these molecules exist, which ones resemble what, and why not knowing what a product actually is remains the single biggest danger of an unregulated market.
Where they come from
Two lineages cross here. One is exploratory: Alexander Shulgin synthesized and described hundreds of phenethylamines and tryptamines (PiHKAL, 1991; TiHKAL, 1997), out of pharmacological and phenomenological curiosity. The other is commercial: from the late 2000s on, labs began mass-producing analogues of controlled substances, sold as "bath salts" or "research chemicals" to stay one step ahead of the law.
That cat-and-mouse game has largely closed: most known families are now scheduled, often by generic structure. Chemical novelty is not a lasting legal loophole, and it was never a safety certificate.
The near twins
At one end of the spectrum sit molecules very close to the classics. 1P-LSD, 1cP-LSD and ALD-52 are prodrugs of LSD: the body converts them into LSD, and the effect is described as nearly indistinguishable. 4-AcO-DMT is a prodrug of psilocin, the active metabolite of psilocybin. Other lysergamides (AL-LAD, ETH-LAD) are active analogues in their own right, with neighbouring profiles.
Close does not mean identical: dose equivalences are approximate, human data are scarce, and purity depends on a market with no oversight at all. But the pharmacological risk carried by these molecules remains broadly comparable to that of their models.
The false twins
At the other end, molecules sold under another molecule's name. The textbook case is the NBOMe family (25I-NBOMe, 25B, 25C), moved on blotter as LSD throughout the 2010s. Active at fractions of a milligram, they fit on paper, but their safety margin is narrow: vasoconstriction, seizures, hyperthermia, and documented deaths, sometimes from two or three tabs. One folk rule captures the difference: if it's bitter, it's a spitter. LSD is tasteless; marked bitterness or a numb tongue points to an NBOMe.
The DOx compounds (DOB, DOC, DOI) are psychedelic amphetamines with a very slow come-up (two to three hours) and a duration of 16 to 30 hours depending on the molecule. The trap is well known: deciding "it isn't working", taking more, and signing up for a full day. Further out still, Bromo-DragonFLY combines extreme duration (up to two or three days) with severe vasoconstriction, including documented cases of necrosis.
A blotter can only carry an active dose of compounds potent at the microgram scale. In practice that narrows the field to four families: lysergamides, NBOMes, DOx, Bromo-DragonFLY. Which is already a map: if a tab is not a lysergamide, everything else on the list is worse.
A blotter is a claim, not a certificate
A name on a product ("Miraculix", "Needlepoint", any batch christening) is marketing, not chemistry. Nobody along the chain, from lab to dealer, stakes anything on the label, and most people in it repeat in good faith whatever they were told. As it happens, Miraculix is also the name of a real German drug-checking laboratory: the same word can name the folklore and its antidote.
A label carries no verifiable information; only analysis does. Reagent tests and drug-checking services are covered on the Harm reduction page.
What an unknown molecule changes
LSD, psilocybin and MDMA drag decades of human data behind them: pharmacology, interactions, contraindications, toxicity. A recent research chemical drags a forum thread. The uncertainty covers everything: the dose-response curve, drug interactions, possible neurotoxicity, long-term effects.
The point is not that all of these molecules are dangerous; the point is that nobody knows, and not knowing forbids precisely what harm reduction makes possible everywhere else: adjusting. With powders, the gap between two doses can come down to a milligram, below the precision of common scales; that is the territory of volumetric dosing and, better still, of quantitative analysis.
Sources
- Erowid, vaults and reports on lysergamides, NBOMes and DOx
- EUDA, formerly EMCDDA, European monitoring of new psychoactive substances
- OFDT, the French drugs observatory, notes on NPS
- DanceSafe, on telling LSD from NBOMe
- Alexander and Ann Shulgin, PiHKAL (1991) and TiHKAL (1997)
- Halberstadt (2017), review of the pharmacology and toxicology of N-benzylphenethylamines (NBOMe)